ANTIBODIES

Contributor Information
- Name Roy Jefferis
- Institute Absolute Antibody ; University of Birmingham
Tool Details
- Tool name: Anti-CD86 [BU63] rAb
- Alternate names: B7.2
- Clone: BU63
- Tool type: Antibodies
- Tool sub-type: Primary Antibody
- Class: Recombinant
- Conjugate: Unconjugated
- Reactivity: Human
- Host: Mouse
- Cancer type: Digestive / Gastrointestinal cancer
- Application: FACS ; IHC ; IF ; IP ; WB
- Description: Recombinant monoclonal antibody directed against CD86 glycoprotein, without impacting on CTLA-4 activity. It aids the investigation of the adaptive immune response system. Background and Research Application CD86 is a 70 kDa type I transmembrane glycoprotein belonging to the immunoglobulin superfamily of cell surface receptors. CD86 was established during the 5th International Leukocyte Differentiation Antigen Workshop. CD86 is expressed on resting monocytes and dendritic cells, activated T and Natural Killer cells. CD86 rapidly induced on the surface of activated B-cells and is the ligand for two different proteins on the T cell surface: CD28, for autoregulation and intercellular association, and CTLA-4, for attenuation of regulation and cellular disassociation. CD86 works in tandem with CD80 to prime T cells in the primary immune response. CD86 is also expressed by malignant Hodgkin and Reed Sternberg (HRS) cells in Hodgkin's disease. This is a recombinant version of anti-CD86 monoclonal antibody. Anti-CD86 BU63, alongside another monoclonal antibody, helped define CD86 single-chain cell-surface protein expressed by blood monocytes and activated B cells. This antibody does not block CTLA-4 binding to B7-2/B70, but induces a conformational change in CD86 which increases the binding affinity of soluble CTLA-4.
- Immunogen: ARH 77 (B-lymphoblastoid cell line)
- Immunogen UniProt ID: P42081
- Isotype: IgG1
- Research area: Immunology
- For Research Use Only
Target Details
- Target: CD86
- Target background: Recombinant monoclonal antibody directed against CD86 glycoprotein, without impacting on CTLA-4 activity. It aids the investigation of the adaptive immune response system. Background and Research Application CD86 is a 70 kDa type I transmembrane glycoprotein belonging to the immunoglobulin superfamily of cell surface receptors. CD86 was established during the 5th International Leukocyte Differentiation Antigen Workshop. CD86 is expressed on resting monocytes and dendritic cells, activated T and Natural Killer cells. CD86 rapidly induced on the surface of activated B-cells and is the ligand for two different proteins on the T cell surface: CD28, for autoregulation and intercellular association, and CTLA-4, for attenuation of regulation and cellular disassociation. CD86 works in tandem with CD80 to prime T cells in the primary immune response. CD86 is also expressed by malignant Hodgkin and Reed Sternberg (HRS) cells in Hodgkin's disease. This is a recombinant version of anti-CD86 monoclonal antibody. Anti-CD86 BU63, alongside another monoclonal antibody, helped define CD86 single-chain cell-surface protein expressed by blood monocytes and activated B cells. This antibody does not block CTLA-4 binding to B7-2/B70, but induces a conformational change in CD86 which increases the binding affinity of soluble CTLA-4.
Application Details
- Application: FACS ; IHC ; IF ; IP ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Storage buffer: PBS with 0.02% azide
- Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
- Shipping conditions: Shipping at 4° C
Related Tools
References
- • Original hybridoma first published in: Nozawa et al. 1993. J Pathol. 169(3):309-15. PMID: 8492223.
- • Santos et al. 2019. Immunology. 157(4):296-303. PMID: 31162836.